Objective,2,To study the clinical efficacy of Mahuang Shengma Decoction in treating patients with chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea-hypopnea syndrome (OSAHS).,Methods,2,Totally 66 patients with COPD and OSAHS were randomly divided into two groups according to random number table method. Thirty-two patients in the control group were given general treatment and routine Western medicine therapy, and 34 cases in the treatment group were additionally given Mahuang Shengma Decoction besides the treatments in the control group. Both groups were treated for 12 weeks. After treatments, changes of traditional Chinese medicine (TCM) syndrome score, apnea hypopnea index (AHI), the lowest oxygen saturation at night (LSaO,2,), the longest time of apnea, apnea index (AI), forced expiratory volume in one second (FEV,1,), and FEV,1, over forced vital capacity (FEV,1,/FVC) in both groups were evaluated, and comparisons were made between groups.,Results,2,①The expectoration score, nocturnal snoring with apnea score, arousal score, and daytime sleepiness score in the treatment group were reduced significantly after treatment (,P,<,0.05), and were remarkably lower than those in the control group (,P,<,0.05). ②In treatment group, AHI, LSaO,2, the longest time of apnea and AI reduced significantly after treatment (,P,<,0.05, or ,P,<,0.01). There were significant differences in AHI, LSaO,2, longest apnea time and AI between the two groups after treatment (,P,<,0.05, or ,P,<,0.01).③FEV,1, and FEV,1,/FVC in the treatment group increased significantly after treatment (,P,<,0.05), and were remarkably higher than those in the control group (,P,<,0.05).,Conclusion,2,Mahuang Shengma Decoction can effectively improve clinical symptoms, lung function and LSaO,2, and reduce AHI, the longest time of apnea and AI in patients with COPD and OSAHS, having good therapeutic effect for COPD and OSAHS.